Centre approves 30% trade-margin cap for non-scheduled cancer medicines

The Centre has approved a trade-margin ceiling of 30% of maximum retail price for cancer medicines outside the scheduled price-control list.

The Department of Pharmaceuticals said on October 8 that prices could fall by up to 70%, with estimated annual patient savings of ₹2,500 crore. These are government projections.

A Directorate General of Health Services expert committee will finalise the medicines covered. The National Pharmaceutical Pricing Authority will subsequently issue a notification.

Source report: PIB, Department of Pharmaceuticals, 8 October 2026.

Image source and licence